Literature DB >> 3857947

Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis.

P J Finan, R J Marshall, E H Cooper, G R Giles.   

Abstract

A review of 90 patients presenting in Leeds over the period 1976-80 with synchronous hepatic metastases from colorectal cancer has been undertaken. The median survival for the group was 10.3 months (range 1-48 months). A multivariate analysis identified factors in the history and examination of the patient, results of biochemical and haematological investigations and characteristics of both the primary and secondary tumour, which influenced survival. Recognition of these factors allowed both a clinical scoring index and computer survival model to be constructed. When applied to the group as a whole both were reasonably accurate at predicting survival (62 per cent for the survival model and 66 per cent for the scoring index). However, the computer model correctly identified 80 per cent of the 'long-term' survivors (greater than 12 months from the time of diagnosis). It is concluded that many trials of therapy for hepatic metastases from colorectal cancer have failed to consider the natural history of the disease and the identification of prognostic indices should allow for adequate stratification within the treatment arms of any future study.

Entities:  

Mesh:

Year:  1985        PMID: 3857947     DOI: 10.1002/bjs.1800720514

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  17 in total

Review 1.  Natural history of liver metastases from colorectal carcinoma.

Authors:  J Norstein; W Silen
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

2.  Treatment for liver metastases from breast cancer: results and prognostic factors.

Authors:  Xiao-Ping Li; Zhi-Qiang Meng; Wei-Jian Guo; Jie Li
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

Review 3.  Resection of liver metastases from a colorectal carcinoma does not benefit the patient.

Authors:  T M Hunt; N Carty; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1990-05       Impact factor: 1.891

4.  Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.

Authors:  Takao Takahashi; Yoshihisa Shibata; Yuichiro Tojima; Kenji Tsuboi; Eiji Sakamoto; Katsuyuki Kunieda; Hiroshi Matsuoka; Kazuyoshi Suzumura; Mikinori Sato; Tatsushi Naganuma; Junichi Sakamoto; Satoshi Morita; Ken Kondo
Journal:  Int J Clin Oncol       Date:  2012-03-02       Impact factor: 3.402

Review 5.  Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.

Authors:  G Scott Gazelle; M G Myriam Hunink; Karen M Kuntz; Pamela M McMahon; Elkan F Halpern; Molly Beinfeld; Jessica S Lester; Kenneth K Tanabe; Milton C Weinstein
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

6.  [Prognostic factors in the evaluation of colorectal liver metastases].

Authors:  T-J Song; P Adusumilli; Y Fong
Journal:  Chirurg       Date:  2005-06       Impact factor: 0.955

7.  Surgery for recurrent colorectal carcinoma--is it worthwhile?

Authors:  S G Pollard; R Macfarlane; W G Everett
Journal:  Ann R Coll Surg Engl       Date:  1989-09       Impact factor: 1.891

8.  Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases.

Authors:  R S Stubbs; R J Cannan; A W Mitchell
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 9.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

Review 10.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases.

Authors: 
Journal:  Surgery       Date:  1988-03       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.